Efficacy and safety of infliximab in patients with Autoimmune Hepatitis

This multicenter retrospective study evaluated infliximab in 42 patients with autoimmune hepatitis (AIH) unresponsive to standard therapies or with concurrent autoimmune diseases.

Back to overview

Infliximab induced clinical remission in 75% of non-responders to second line and in 46% of patients failing third line therapies. Treatment was discontinued in 3 patients ( 1 for anaphylaxis and 2 others developed infliximab antibodies). The findings suggest infliximab is a promising rescue option for difficult-to-treat AIH.

Fore more information, please follow this link.